CAM
NBIX icon

Covenant Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Covenant Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,343
Closed -$3.9M – 175
2024
Q2 		$3.9M Buy
28,343
+37
+0.1% +$5.07K 0.62% 46
2024
Q1 		$3.9M Buy
28,306
+535
+2% +$73.1K 0.64% 42
2023
Q4 		$3.66M Sell
27,771
-2,280
-8% -$262K 0.66% 41
2023
Q3 		$3.38M Buy
30,051
+11,628
+63% +$1.22M 0.89% 38
2023
Q2 		$1.74M Sell
18,423
-85
-0.5% -$8.3K 0.44% 69
2023
Q1 		$1.87M Buy
+18,508
New +$1.93M 0.45% 70

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Covenant Asset Management's NBIX Position: Q3 2024 in Review

Covenant Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 28,343 shares — an estimated $3.9M sold.

Covenant Asset Management first reported a position in NBIX in Q1 2023 and held it in 6 quarters. The position peaked at $3.9M in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Covenant Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Covenant Asset Management sold 28,343 Neurocrine Biosciences shares in Q3 2024, an estimated $3.9M.
  • Covenant Asset Management first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 6 quarters.
  • Covenant Asset Management's Neurocrine Biosciences position peaked at $3.9M in Q1 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Covenant Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.